Nasal congestion is an inconvenient and uncomfortable medical condition that can have many causes. The symptoms of nasal congestion can include a blocked, stuffy, or runny nose, fever, eye redness, headaches, difficulty breathing, and more.
There are many different solutions available on the market today that are intended to provide relief from the effects of nasal congestion, but the most effective are nasal sprays.
Nasal sprays are small aerosol delivery systems that are used to dispense anti-inflammatory substances to the mucous membranes of the sinuses, usually in the form of corticosteroids.
These solutions have been clinically proven to deliver fast and effective relief from the symptoms of nasal congestion, but in many cases can cause unwanted side effects when used too frequently.
Prolonged usage of less safe nasal sprays has been linked to side effects such as severe ongoing nosebleeds, white patches or sore areas in the mouth or throat, inhibited healing ability in the body, fever, chills, and flu-like symptoms.
A new nasal spray solution from Amneal Pharmaceuticals LLC, however, is shaping up to be one of the most promising and safest nasal spray solutions of the last decade.
Mometasone Furoate Nasal Spray is a new nasal spray solution and the first of its kind from Amneal Pharmaceuticals LLC.
Consisting of a new topical steroid called mometasone furoate, the Nasonex Generic formula is being manufactured in the Anneal Pharmaceuticals Branchburg, N.J. production facility and will begin shipping to consumers via wholesalers, direct trade, and distributors later this month.
In this article, we’ll take a look at Mometasone Furoate Nasal Spray and find out what makes it different than other nasal sprays to help you decide whether it’s the right nasal decongestant for your needs.
Nasonex has been available as a non-generic prescription for several years now, but the FDA has just recently approved the release of a new generic form of the highly popular nasal decongestant.
The brand is already one of the most popular and profitable nasal decongestants available on the market, with the current branded solution manufactured by Merck earning roughly $955.5 million in sales for the year ending January 2016.
The executive vice president of sales and marketing at Amneal Pharmaceuticals, Jim Luce, has stated that the release of the new generic form of the solution represents another example of the way in which the company is continuing to expand into newer and more complex dosage forms.
Aside from intranasal sprays, the company plans to expand into delivery methods such as chewable tablets, metered dose inhalers, and transdermal patches.
Mometasone Furoate Nasal Spray is intended to provide affordable support to individuals that are suffering from conditions such as year-round allergies, runny noses, sneezing, and other symptoms of nasal congestion.
Each Mometasone Furoate Nasal Spray device from Amneal is available in a 50 mcg/spray strength, and will be provided to consumers packaged in a high-density polyethylene bottle.
Like most nasal spray solutions, the Nasonex generic bottle is white, but has a turquoise cap that covers a manual pump applicator. Weighing in at 17 grams, each bottle delivers 120 doses.
The official uses of Nasonex Generic are listed as treatment for seasonal allergies and nasal congestion in individuals beyond two years of age, the prevention of allergic rhinitis in individuals beyond the age of twelve, and as a treatment for nasal polyps in individuals beyond the age of 18.
Nasonex Generic is prescription-only, and must be dispensed with the label to ensure that the patient complies with dosage instruction.
The active ingredient in Mometasone Furoate Nasal Spray is mometasone furoate. As a topical steroid, mometasone furoate performs an anti-inflammatory function that minimizes skin swelling and irritation.
When used as an intranasal spray, mometasone furoate is a powerful decongestant that has many positive properties with negligible side effects.
Mometasone furoate is one of the most widely-tested and effective treatments for nasal congestion available on the market.
A systematic review of the use of mometasone furoate was performed in a joint investigative venture by the University of Siena and the University of Rome in 2016, which found that, when compared to all other nasal decongestant solutions on the market, mometasone furoate shows greater symptom control and is a more reliable treatment.
The study assessed more than 300 different individual peer-reviewed studies into the clinical effects of mometasone furoate and ruled that, based on the 17 years of scientific evidence supporting its use, mometasone furoate offers proven long term efficacy and safety.
Amneal, in bringing mometasone furoate and the Nasonex solution to the generic market, is making effective and safe solutions available to a broad spectrum of Americans that previously found it inaccessible.
Mometasone Furoate Nasal Spray from Amneal Pharmaceuticals is expected to have a wholesale purchase cost of $284.72, and will be available from most medical clinics by Q2 2017.
1. https://www.ncbi.nlm.nih.gov/pubmed/27141307 ↑